Rivaroxaban Uses, Dosage, Side Effects & Warnings | DrugsAtlas
Authoritative Clinical Reference
Navigation
Therapeutic Class
Anticoagulant
Subclass
Direct Oral Anticoagulant (DOAC) ā Factor Xa inhibitor
Speciality
Haematology
Schedule (India)
Schedule H
Routes
Oral
Formulations
- Tablets: 2.5 mg, 10 mg, 15 mg, 20 mg
Note: Oral suspension/granules NOT AVAILABLE in India
Adult indications
INDICATIONS + DOSING ā FOR CLINICIAN USE ONLY
Primary Indications (Approved / Standard in India)
1. Prevention of Stroke and Systemic Embolism in Non-Valvular Atrial Fibrillation (NVAF)
Adults with CrCl ≥50 mL/min:
| Parameter | Recommendation |
|---|---|
| Starting dose | 20 mg once daily with food (evening meal preferred) |
| Titration | Not applicable |
| Usual maintenance dose | 20 mg once daily |
| Maximum dose | 20 mg/day |
Adults with CrCl 15ā49 mL/min:
| Parameter | Recommendation |
|---|---|
| Starting dose | 15 mg once daily with food |
| Titration | Not applicable |
| Usual maintenance dose | 15 mg once daily |
| Maximum dose | 15 mg/day |
Clinical Notes:
- Avoid if CrCl <15 mL/min
- Must be taken with food to ensure adequate bioavailability (15 mg and 20 mg doses)
- Contraindicated in valvular AF (mechanical prosthetic valves, moderate-to-severe mitral stenosis)
2. Treatment of Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE)
Adults ā Acute Treatment Phase (Days 1ā21):
| Parameter | Recommendation |
|---|---|
| Starting dose | 15 mg twice daily with food |
| Titration | Not applicable during loading phase |
| Duration | 21 days |
| Maximum dose | 30 mg/day (during loading phase) |
Adults ā Maintenance Phase (Day 22 onwards):
| Parameter | Recommendation |
|---|---|
| Starting dose | 20 mg once daily with food (from Day 22) |
| Titration | Not applicable |
| Usual maintenance dose | 20 mg once daily |
| Maximum dose | 20 mg/day |
Clinical Notes:
- Minimum treatment duration: 3 months
- Provoked VTE (reversible risk factor): 3 months usually sufficient
- Unprovoked or recurrent VTE: consider extended therapy beyond 3 months
- Assess bleeding risk periodically during long-term therapy
3. Prevention of Recurrent DVT and PE (Extended Secondary Prevention)
Adults ā After Completion of Initial Treatment:
| Parameter | Recommendation |
|---|---|
| Starting dose | 10 mg once daily (with or without food) |
| Titration | Not applicable |
| Usual maintenance dose | 10 mg once daily |
| Maximum dose | 20 mg once daily (may be used if high recurrence risk) |
Clinical Notes:
- Initiate after at least 6 months of standard anticoagulation
- 20 mg dose may be preferred if VTE recurred during anticoagulation or very high risk
- Periodically reassess need for continued therapy versus bleeding risk
4. Prophylaxis of VTE after Elective Hip or Knee Replacement Surgery
Adults:
| Parameter | Recommendation |
|---|---|
| Starting dose | 10 mg once daily |
| Timing of first dose | 6ā10 hours post-surgery, after haemostasis established |
| Titration | Not applicable |
| Usual maintenance dose | 10 mg once daily |
| Maximum dose | 10 mg/day |
Duration:
- Knee replacement: 14 days
- Hip replacement: 35 days
Clinical Notes:
- May be taken with or without food (10 mg dose)
- Delay initiation if surgical haemostasis concerns
- Avoid if neuraxial catheter in situ (remove catheter before starting; see Cautions)
5. Secondary Prevention of Atherothrombotic Events in Chronic Coronary Artery Disease (CAD) or Peripheral Arterial Disease (PAD)
Adults ā In Combination with Aspirin:
| Parameter | Recommendation |
|---|---|
| Starting dose | Rivaroxaban 2.5 mg twice daily + Aspirin 75ā100 mg once daily |
| Titration | Not applicable |
| Usual maintenance dose | Rivaroxaban 2.5 mg twice daily + Aspirin 75ā100 mg once daily |
| Maximum dose | 5 mg/day rivaroxaban (2.5 mg twice daily) |
Clinical Notes:
- Indicated for stable atherosclerotic vascular disease
- Contraindicated in patients with prior stroke or TIA ā increased intracranial bleeding risk
- Continue long-term for secondary prevention
- May be taken with or without food (2.5 mg dose)
Secondary Indications ā Adults Only (Off-label)
| Indication | Dose | Duration | Supervision | Evidence Basis |
|---|---|---|---|---|
|
Left Ventricular Thrombus ā OFF-LABEL
|
20 mg once daily with food (15 mg if CrCl 15ā49) | Minimum 3 months; reassess with imaging | Specialist only (Cardiology) | Indian cardiology practice; observational studies suggest comparable efficacy to warfarin |
|
Heparin-Induced Thrombocytopenia (HIT) ā OFF-LABEL
|
15 mg BD for 21 days, then 20 mg OD | Until platelet recovery and clinical stability | Specialist only (Haematology) | Limited evidence; emerging practice when argatroban/fondaparinux unavailable |
|
Antiphospholipid Syndrome (APS) ā Triple-Positive ā OFF-LABEL
|
NOT RECOMMENDED ā Warfarin preferred | ā | ā | TRAPS trial showed inferior outcomes with rivaroxaban; avoid in high-risk APS |
Paediatric indications
PAEDIATRIC DOSING (Specialist Only)
Primary Indications
Regulatory Status: NOT approved for routine paediatric use in India. Paediatric oral suspension formulation NOT AVAILABLE in India.
Age Restriction: Not recommended below 18 years except under specialist haematology/cardiology supervision.
Secondary Indications ā Paediatric (Off-label)
Treatment of Acute VTE in Children ā OFF-LABEL
Use only when LMWH or warfarin unsuitable and under specialist supervision
Minimum Age/Weight: ≥6 months of age, ≥2.6 kg body weight
| Body Weight | Approximate Daily Dose | Administration |
|---|---|---|
| 2.6ā<12 kg | Weight-band based ā requires specialist calculation | Crushed tablets in water/apple puree (not ideal; suspension not available) |
| 12ā<30 kg | 10ā15 mg/day in 1ā2 divided doses | With food |
| ≥30 kg | 15ā20 mg once daily | With food |
Clinical Notes:
- Dosing extrapolated from international paediatric trials (EINSTEIN-Jr)
- Lack of appropriate paediatric formulation in India limits practical use
- LMWH remains preferred anticoagulant in paediatric VTE in India
- Requires close specialist supervision (paediatric haematology/cardiology)
Safety Monitoring:
- CBC, renal function, liver function at baseline and periodically
- Clinical monitoring for bleeding
- Anti-Xa levels generally not required but may be considered in complex cases
Renal Adjustments
Rivaroxaban is approximately 33% renally excreted ā dose adjustment required in renal impairment:
| Indication | CrCl ≥50 mL/min | CrCl 30ā49 mL/min | CrCl 15ā29 mL/min | CrCl <15 mL/min |
|---|---|---|---|---|
| NVAF (stroke prevention) | 20 mg OD | 15 mg OD | 15 mg OD (use with caution) | Avoid |
| VTE treatment (acute) | 15 mg BD → 20 mg OD | 15 mg BD → 20 mg OD | Use with caution; limited data | Avoid |
| VTE prevention (orthopaedic) | 10 mg OD | 10 mg OD | 10 mg OD (use with caution) | Avoid |
| Extended VTE prevention | 10 mg OD | 10 mg OD | Use with caution | Avoid |
| CAD/PAD + Aspirin | 2.5 mg BD | 2.5 mg BD | Use with caution | Avoid |
Dialysis:
- Haemodialysis: Not recommended ā rivaroxaban is highly protein-bound and not effectively dialysed
- Peritoneal dialysis: Avoid ā insufficient data
Monitoring: Reassess renal function every 6 months in stable patients; more frequently if acute illness, dehydration, or nephrotoxic drugs used.
Hepatic adjustment
Contraindications
- Active clinically significant bleeding (including GI, intracranial, or any site)
- Hepatic disease associated with coagulopathy and clinically relevant bleeding risk
- Severe renal impairment (CrCl <15 mL/min)
- Known hypersensitivity to rivaroxaban or excipients
- Pregnancy (particularly second and third trimesters)
- Lesions at high risk of clinically significant bleeding (e.g., active peptic ulcer, recent brain/spinal surgery, intracranial neoplasm)
- Concomitant treatment with any other anticoagulant (except during transition periods)
- Concomitant use with strong CYP3A4 and P-glycoprotein inhibitors (e.g., ketoconazole, itraconazole, ritonavir, lopinavir)
- Mechanical prosthetic heart valves
- Moderate-to-severe mitral stenosis of rheumatic origin
Cautions
- Moderate renal impairment (CrCl 15ā49 mL/min) ā dose reduction may be needed; monitor closely
- Elderly patients (≥75 years) ā increased bleeding risk
- Low body weight (<50 kg) ā potential for increased drug exposure
- Concomitant use of antiplatelet agents (aspirin, clopidogrel, prasugrel, ticagrelor) ā additive bleeding risk
- Chronic NSAID use ā increased GI bleeding risk
- Recent major surgery or trauma
- History of GI bleeding or peptic ulcer disease
- Uncontrolled severe hypertension
- Bronchiectasis or history of pulmonary bleeding
- Neuraxial anaesthesia or spinal puncture ā risk of epidural/spinal haematoma
-
- Delay rivaroxaban for at least 18 hours after catheter removal
- Remove catheter at least 18 hours after last rivaroxaban dose
- Moderate hepatic impairment (Child-Pugh B) ā increased exposure
- Patients with antiphospholipid syndrome (especially triple-positive) ā warfarin preferred
Pregnancy
| Parameter | Details |
|---|---|
| Risk category | Contraindicated ā crosses placenta; potential for fetal bleeding, teratogenicity (animal data) |
| Preferred alternatives | Low Molecular Weight Heparin (LMWH) ā enoxaparin is anticoagulant of choice in pregnancy in India |
| When may be used | Only in exceptional circumstances if LMWH absolutely contraindicated and no alternative exists; requires specialist decision |
| Monitoring | If inadvertent exposure: fetal ultrasound for anomalies, monitor for bleeding; plan delivery with haematology input |
Lactation
| Parameter | Details |
|---|---|
| Compatibility | Not recommended during breastfeeding |
| Drug levels in milk | Excreted in breast milk; infant exposure uncertain |
| Preferred alternatives | LMWH (enoxaparin) ā not excreted in breast milk; warfarin ā compatible with breastfeeding |
| Infant monitoring | If exposure occurs: monitor for bleeding signs, bruising, feeding difficulties |
Elderly
| Parameter | Recommendation |
|---|---|
| Starting dose | Same as younger adults, but assess renal function before prescribing |
| Titration | Not applicable ā fixed dosing regimen |
| Special risks | Increased bleeding risk (particularly GI and intracranial); higher prevalence of renal impairment; falls risk; polypharmacy with interacting drugs |
| Monitoring | Renal function at baseline and every 6 months; more frequently if acute illness; regular clinical assessment for bleeding |
Major drug interactions
| Drug/Class | Mechanism/Effect | Recommendation |
|---|---|---|
| Strong CYP3A4 + P-gp inhibitors (ketoconazole, itraconazole, voriconazole, posaconazole, ritonavir, lopinavir) | Marked increase in rivaroxaban exposure → high bleeding risk |
Contraindicated ā avoid concomitant use
|
| Strong CYP3A4 inducers (rifampicin, rifabutin, carbamazepine, phenytoin, phenobarbital, St. John's Wort) | Significant reduction in rivaroxaban levels → loss of efficacy |
Avoid ā therapeutic failure likely
|
| Other anticoagulants (warfarin, LMWH, UFH, fondaparinux, other DOACs) | Additive anticoagulant effect → major bleeding risk |
Avoid ā exception: brief overlap during transition (specialist supervision)
|
| Thrombolytics (alteplase, tenecteplase, streptokinase) | Markedly increased bleeding risk |
Avoid concomitant use; hold rivaroxaban during thrombolysis
|
| Dual antiplatelet therapy (DAPT ā aspirin + P2Y12 inhibitor) | Significantly increased bleeding risk | Use with extreme caution; triple therapy duration should be minimised; specialist decision |
Moderate drug interactions
| Drug/Class | Effect | Recommendation |
|---|---|---|
| Single antiplatelet (aspirin, clopidogrel) | Increased bleeding risk | Use only when indicated (CAD/PAD); monitor for bleeding |
| NSAIDs (diclofenac, ibuprofen, naproxen) | Increased GI bleeding risk | Avoid chronic use; if short-term use required, consider gastroprotection |
| Moderate CYP3A4 inhibitors (erythromycin, clarithromycin, fluconazole, diltiazem, verapamil) | Modest increase in rivaroxaban levels | Use with caution; monitor for bleeding |
| Dronedarone | Increases rivaroxaban exposure | Avoid if possible; if used, monitor closely |
| Amiodarone | Mild increase in rivaroxaban levels | Generally acceptable; monitor for bleeding |
| SSRIs/SNRIs (fluoxetine, sertraline, venlafaxine) | Increased bleeding tendency (platelet effect) | Monitor for bleeding; counsel patient |
| Proton pump inhibitors | No significant interaction | Can be used together; useful for gastroprotection |
Common Adverse effects
- Bleeding ā minor (epistaxis, gingival bleeding, bruising, menorrhagia)
- Anaemia (may be occult GI blood loss)
- Nausea, dyspepsia
- Diarrhoea or constipation
- Dizziness
- Headache
- Peripheral oedema
- Mild transaminase elevation
- Fatigue
Serious Adverse effects
| Adverse Effect | Clinical Action |
|---|---|
| Major bleeding (GI haemorrhage, intracranial haemorrhage, retroperitoneal bleeding) |
Immediate discontinuation; supportive care; consider reversal agent (andexanet alfa if available) or prothrombin complex concentrate; hospitalisation
|
| Spinal/Epidural haematoma (with neuraxial procedures) |
Emergency ā can cause permanent paralysis; urgent neurosurgical consultation
|
| Severe hypersensitivity/Anaphylaxis | Discontinue immediately; emergency management |
| Hepatotoxicity (rare) | Discontinue if significant transaminase elevation (>3× ULN with symptoms) |
| Thrombocytopenia (rare) | Monitor; may need to discontinue |
| Compartment syndrome (in setting of bleeding) | Surgical emergency |
Reversal in Major Bleeding:
- Andexanet alfa ā specific reversal agent (limited availability in India)
- Prothrombin Complex Concentrate (PCC) ā 4-factor PCC 25ā50 units/kg
- Tranexamic acid ā adjunctive
- Activated charcoal ā if ingestion within 2 hours
- No role for FFP, vitamin K, or protamine
Monitoring requirements
Baseline:
- Complete blood count (haemoglobin, platelet count)
- Renal function (serum creatinine, calculated CrCl)
- Liver function tests (transaminases, bilirubin)
- Coagulation screen (PT/INR) ā for baseline documentation only, not for monitoring
- Bleeding risk assessment (HAS-BLED score for AF patients)
After Initiation / Dose Change:
- Clinical assessment for bleeding at 1 month
- Renal function at 1ā3 months (especially in elderly, CKD, acute illness)
- Haemoglobin if bleeding suspected
Long-term Monitoring:
- Renal function: Every 6ā12 months in stable patients; more frequently if CrCl <60 or at-risk (elderly, diabetes, heart failure, dehydration)
- Haemoglobin and haematocrit: Annually or if bleeding symptoms
- Liver function: Annually or if symptoms suggestive of hepatotoxicity
- Clinical bleeding assessment at every visit
- Reassess indication and bleeding risk annually
Note: Routine coagulation monitoring (PT/INR, aPTT) not required and not reliable for assessing rivaroxaban effect. Anti-Xa chromogenic assay (rivaroxaban-calibrated) may be used in special situations (overdose, emergency surgery, extremes of body weight).
Brands in India
Originator:
- Xarelto (Bayer/Zydus)
Generic/Licensed Brands:
- Rivasmart (Cipla)
- Xaban (Dr. Reddy's)
- Rivaxo (Sun Pharma)
- Rivaxa (Torrent)
- Rivonex (Mankind)
- Xeralto (Macleods)
- Rixova (Intas)
- Rivaz (Alkem)
Fixed-Dose Combinations:
- Rivaroxaban 2.5 mg + Aspirin 75 mg/100 mg ā available from select manufacturers for CAD/PAD indication
Price range (INR)
| Formulation | Approximate Price per Tablet |
|---|---|
| Tablet 2.5 mg | ā¹12āā¹25 |
| Tablet 10 mg | ā¹25āā¹50 |
| Tablet 15 mg | ā¹40āā¹70 |
| Tablet 20 mg | ā¹55āā¹95 |
- Not currently under NPPA price control
- Not included in NLEM 2022
- Significant price variation between originator and generic brands
- Generic options substantially more affordable
Clinical pearls
- Food is essential for higher doses ā 15 mg and 20 mg doses must be taken with food to ensure adequate bioavailability (~66% fasting vs ~100% with food); 2.5 mg and 10 mg can be taken with or without food
- Not for valvular AF ā rivaroxaban is contraindicated in mechanical prosthetic valves and moderate-to-severe rheumatic mitral stenosis; use warfarin for these patients
- Renal function determines dose in AF ā always calculate CrCl (Cockcroft-Gault); if CrCl 15ā49 mL/min, use 15 mg OD; avoid if <15 mL/min
- No bridging required ā unlike warfarin, rivaroxaban has rapid onset (2ā4 hours) and offset; avoid overlapping with LMWH except in specific transition scenarios
- Beware triple therapy ā combination with DAPT (aspirin + P2Y12 inhibitor) markedly increases bleeding; minimise duration and consider 15 mg OD or 2.5 mg BD rivaroxaban in this setting (specialist decision)
- Specific reversal agent availability is limited ā andexanet alfa not widely available in India; PCC is the practical option for major bleeding
- Prior stroke/TIA contraindicates vascular dose ā do NOT use rivaroxaban 2.5 mg + aspirin combination in patients with prior stroke or TIA (intracranial bleeding risk)
Version
RxIndia v1.0 ā 05 Jun 2025
Reference
-
- CDSCO approved product inserts
- Indian Pharmacopoeia
- API Textbook of Medicine
- AIIMS Anticoagulation Protocols
- Cardiological Society of India ā AF and VTE management recommendations
- Bayer India Xarelto Prescribing Information
- Goodman & Gilman's The Pharmacological Basis of Therapeutics (supportive)
- EINSTEIN-DVT, EINSTEIN-PE, ROCKET-AF, COMPASS trials (for indication context)
- EINSTEIN-Jr trial (for paediatric off-label context)
āļø
Clinical Responsibility
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Content Feedback
Is this information helpful?
Help us improve our clinical database for the medical community.